The Eastern Cooperative Oncology Group (ECOG) is a multidisciplinary cancer clinical trials research group dedicated to the treatment, prevention, and cure of adult malignancies. The Operations Office grant application requests funding to support the activities of the group headquarters. Under the direction of the Principal Investigator, Robert L. Comis, MD, the ECOG Operations office is responsible for organizing and coordinating the scientific and administrative activities of the Group;these activities include protocol development, correlative study development, dissemination of necessary information to Group members, organization of Group meetings, maintenance of Group membership and publications, monitoring of compliance with regulatory requirements, adverse event (AE) reporting and review, administration of the audit program, the development and maintenance of standard operating procedures (SOPs), and the management and disbursement of Group funds. Funding requested by the ECOG Operations Office Grant includes support for the Chairs of the ECOG Scientific and Administrative Committees. Additionally funding is requested in this application for member institution accruals to therapeutic and non-therapeutic clinical trials. This application requests funding for the period 05/01/2010 - 04/30/2016.

Public Health Relevance

The primary goal of the ECOG Operations Office is to provide the support necessary to conduct relevant and rigorous clinical trials, which benefit public health by improving the quality and standard of care for cancer patients.

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Cooperative Clinical Research--Cooperative Agreements (U10)
Project #
5U10CA021115-39
Application #
8468573
Study Section
Subcommittee G - Education (NCI)
Program Officer
Mooney, Margaret M
Project Start
1992-09-01
Project End
2014-02-28
Budget Start
2013-05-01
Budget End
2014-02-28
Support Year
39
Fiscal Year
2013
Total Cost
$9,389,476
Indirect Cost
$1,199,351
Name
Frontier Sci & Technology Rsch Fdn, Inc
Department
Type
DUNS #
080330186
City
Boston
State
MA
Country
United States
Zip Code
02215
Lubner, Sam; Feng, Yang; Mulcahy, Mary et al. (2018) E4206: AMG 706 and Octreotide in Patients with Low-Grade Neuroendocrine Tumors. Oncologist 23:1006-e104
Moots, Paul L; O'Neill, Anne; Londer, Harold et al. (2018) Preradiation Chemotherapy for Adult High-risk Medulloblastoma: A Trial of the ECOG-ACRIN Cancer Research Group (E4397). Am J Clin Oncol 41:588-594
Ignatz-Hoover, James J; Wang, Victoria; Mackowski, Nathan M et al. (2018) Aberrant GSK3? nuclear localization promotes AML growth and drug resistance. Blood Adv 2:2890-2903
Gravis, Gwenaelle; Boher, Jean-Marie; Chen, Yu-Hui et al. (2018) Burden of Metastatic Castrate Naive Prostate Cancer Patients, to Identify Men More Likely to Benefit from Early Docetaxel: Further Analyses of CHAARTED and GETUG-AFU15 Studies. Eur Urol 73:847-855
Francis, Prudence A; Pagani, Olivia; Fleming, Gini F et al. (2018) Tailoring Adjuvant Endocrine Therapy for Premenopausal Breast Cancer. N Engl J Med 379:122-137
Lemieux, Julie; Brundage, Michael D; Parulekar, Wendy R et al. (2018) Quality of Life From Canadian Cancer Trials Group MA.17R: A Randomized Trial of Extending Adjuvant Letrozole to 10 Years. J Clin Oncol 36:563-571
Ailawadhi, Sikander; Jacobus, Susanna; Sexton, Rachael et al. (2018) Disease and outcome disparities in multiple myeloma: exploring the role of race/ethnicity in the Cooperative Group clinical trials. Blood Cancer J 8:67
Samlowski, Wolfram E; Moon, James; Witter, Merle et al. (2017) High frequency of brain metastases after adjuvant therapy for high-risk melanoma. Cancer Med 6:2576-2585
Sparano, Joseph A; Gray, Robert; Oktay, Maja H et al. (2017) A metastasis biomarker (MetaSite Breastâ„¢ Score) is associated with distant recurrence in hormone receptor-positive, HER2-negative early-stage breast cancer. NPJ Breast Cancer 3:42
Saha, Poornima; Regan, Meredith M; Pagani, Olivia et al. (2017) Treatment Efficacy, Adherence, and Quality of Life Among Women Younger Than 35 Years in the International Breast Cancer Study Group TEXT and SOFT Adjuvant Endocrine Therapy Trials. J Clin Oncol 35:3113-3122

Showing the most recent 10 out of 753 publications